MétaCan
Menu
← Back to cohort
Record W4405096090 · doi:10.1182/blood-2024-204249

The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes

2024· article· en· W4405096090 on OpenAlexaffabout
Mohammed Kawari, Mariana Pinto Pereira, Mats Remberger, Ambrose Lau, Arjun Law, Rajat Kumar, Igor Novitzky‐Basso, Wilson Lam, Ivan Pašić, Armin Gerbitz, Auro Viswabandya, Dennis Dong Hwan Kim, Jonas Mattsson, Fotios V. Michelis

Bibliographic record

VenueBlood · 2024
Typearticle
Languageen
FieldMedicine
TopicTransplantation: Methods and Outcomes
Canadian institutionsUniversity Health NetworkPrincess Margaret Cancer CentreUniversity of Toronto
Fundersnot available
KeywordsComorbidityIncidence (geometry)MedicineGraft-versus-host diseaseLungInternal medicineDiseaseLung transplantationPulmonary diseaseIntensive care medicine

Abstract

fetched live from OpenAlex

Introduction: Allogeneic hematopoietic cell transplantation (Allo-HCT) is the curative treatment for various hematological disorders. Despite advancements in supportive care, graft-versus-host disease (GVHD) continues to be a challenging complication. Smoking is linked with various pulmonary diseases, also elevates the risk of pulmonary complications and overall mortality in Allo-HCT recipients. However, it remains unclear whether smoking adversely affects Allo-HCT outcomes independently of pre-transplant underlying lung conditions. Methodology: We conducted a retrospective analysis of 407 patients (pts) who underwent Allo-HCT at Princess Margaret Cancer Centre, Toronto between January 2019 and May 2021. This analysis examined the impact of pre-transplant pulmonary comorbidities, smoking history, and total smoking dose on transplant outcomes. Pre-transplant pulmonary comorbidity was defined according to HCT-specific comorbidity index: DLCO and/or FEV1 less than 80%, or dyspnea on slight activity. Four groups were formed based on smoking history and pre-transplant pulmonary comorbidity. Group A: smoker with pre-transplant pulmonary comorbidity, 40 pts (9.8%). Group B: non-smoker with pre-transplant pulmonary comorbidity, 71 pts (17.4%). Group C: smoker with no pre-transplant pulmonary comorbidity, 105 pts (25.8%). Group D: non-smoker with no pre-transplant pulmonary comorbidity, 191 pts (46.9%). Smokers were categorized into three groups based on their smoking history <10 pack-years (59 pts, 14.5%), 10 to 25 pack-years (50 pts, 12.3%), and >25 pack-years (35 pts, 8.6%). The primary end point is the incidence of lung GVHD. Secondary end points are the 3 year-overall survivor (OS) and Non-Relapse Mortality (NRM). Results: Among the 407 pts, the median age was 58 years (18-76). Of these patients, 94 (23.1%) received grafts from matched related donors, 195 (47.9%) had match unrelated graft, while 79 (19.4%) and 39 (9.6%) had haploidenitcal donor and mismatch unrelated donor, respectively. Two-thirds of the patients, 264 (64.9%), received dual T cell depletion for GVHD prophylaxis, consisting of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy). Additionally, 81 pts (19.9%) received only ATG, while 54 pts (13.3%) received only PTCy. The median number of readmission days in the first year was 45 days for the group A, compared to 36, 31, and 34 days in group B, C and D, respectively (p=0.007). However, there was no difference in the ICU admissions across the four groups (p=0.2). The 3-year OS for the entire cohort is 65.3% (95% CI: 60.5-69.8), with a NRM of 18.0% (95% CI: 14.4-21.9). The incidence of chronic GVHD is 37.9% (95% CI: 33.0-42.9). The 3-year OS is lowest in Group A at 45.0% (95% CI: 29.3-59.5), compared to 70.4% (95% CI: 58.3-79.6) in Group B, 62.4% (95% CI: 52.3-70.9) in Group C, and 69.4% (95% CI: 62.3-75.5) in Group D (p=0.006). The combination of smoking and pre-transplant pulmonary comorbidities adversely affects NRM, which is 37.5% (95% CI: 22.6-52.3) in this group, while it is 15.5% (95% CI: 8.2-24.9), 18.2% (95% CI: 11.5-26.2), 14.7% (95% CI: 10.1-20.1) in group B, C, and D, respectively (p=0.001). There were no significant differences among the four groups in the incidence of grade II-IV acute GVHD or chronic GVHD, with p-values of 0.32 and 0.75, respectively. However, Group A had a higher incidence of chronic lung GVHD compared to the other groups (p=0.01). Patients with >25 pack-years smoking history had the lowest 3-year OS at 45.5% (95% CI: 28.7-60.9), compared to 49.5% (95% CI: 35.0-62.5) for those with 11-25 pack-years and 70.5% (95% CI: 56.8-80.5) for those with <10 pack-years (p=0.02). There were no differences in NRM among the three smoking history groups (p=0.26). Nonetheless, relapse-free survival (RFS) was higher in the group with a lower smoking history of <10 pack-years (p=0.02). In the multivariate analysis (MVA), a longer smoking history of >10 pack-years is associated with higher mortality and reduced RFS. Conclusion: The results exhibit the combination of smoking and pre-transplant pulmonary comorbidities increases the incidence of chronic lung GVHD. This association also correlates with a lower 3-year OS and higher NRM. Moreover, a higher smoking dose is associated with reduced OS. Further research is required to determine the ideal intervention for optimizing outcomes in smokers with pre-transplant pulmonary comorbidities.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.010
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.300
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueBlood→Same topicTransplantation: Methods and Outcomes→French-language works237,207→